Hirudin suppresses hematogenous metastasis by targeting desmosome junction transition in circulating tumor cell clusters via HIF-1α–DSG2 signaling
9.0
来源：
Nature
关键字：
siRNA
发布时间：
2025-12-12 15:33
摘要：
Hirudin, an anticoagulant peptide, has been identified as a promising agent for inhibiting breast cancer metastasis by targeting circulating tumor cell (CTC) clusters. The study reveals that hirudin disrupts desmosome junctions mediated by DSG2 through the HIF-1α signaling pathway, leading to decreased cluster stability and reduced metastatic potential. This research underscores the importance of CTC clusters in cancer progression and positions hirudin as a potential therapeutic candidate in oncology.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分
business_impact
1.0分
scientific_rigor
1.5分
timeliness_innovation
1.5分
investment_perspective
2.5分
market_value_relevance
1.0分
team_institution_background
0.5分
technical_barrier_competition
1.0分
关键证据
Hirudin inhibits hematogenous metastasis of breast cancer through suppression of HIF-1α-controlled DSG2-mediated desmosome junctions.
The study identifies the therapeutic potential of targeting HIF-1α and DSG2 in CTC clusters.
Hirudin's mechanism involves disrupting intercellular adhesion and promoting the conversion of junction types.
真实性检查
否
AI评分总结
Hirudin, an anticoagulant peptide, has been identified as a promising agent for inhibiting breast cancer metastasis by targeting circulating tumor cell (CTC) clusters. The study reveals that hirudin disrupts desmosome junctions mediated by DSG2 through the HIF-1α signaling pathway, leading to decreased cluster stability and reduced metastatic potential. This research underscores the importance of CTC clusters in cancer progression and positions hirudin as a potential therapeutic candidate in oncology.